Abstract
IgE plays a central role in the pathophysiology of allergic disorders. A humanized, monoclonal anti-IgE-antibody in the form of omalizumab is now available, which has a selective effect on the allergic disease process. This antibody binds exclusively to freely circulating IgE. Phase III studies in children and adults consistently showed that treatment with anti-IgE (omalizumab) led to significant reduction of asthma exacerbations and clinical complaints as well as intake of medication for asthma and allergic rhinitis. In another study approach for patients with a food allergy (peanuts), anti-IgE effected a higher tolerated allergic dose in oral provocation tests. The latter effect provides the possibility for preventive intervention in the allergic disease process with anti-IgE.
Translated title of the contribution | Anti-IgE-antibody (omalizumab). Indication for treatment in pediatrics |
---|---|
Original language | German |
Journal | Monatsschrift fur Kinderheilkunde |
Volume | 152 |
Issue number | 7 |
Pages (from-to) | 782-785 |
Number of pages | 4 |
ISSN | 0026-9298 |
DOIs | |
Publication status | Published - 07.2004 |
Research Areas and Centers
- Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)